Alzinova AB
ALZ.XSTO
Alzinova AB is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease. The company’s work centers on immunotherapy approaches designed to target toxic amyloid-beta oligomers, a form of protein aggregate associated with the disease process. Its portfolio includes ALZ-101, a therapeutic vaccine candidate, and ALZ-201, a monoclonal antibody program aimed at neutralizing harmful oligomers. Alzinova’s proprietary AβCC peptide technology underpins its research platform and supports the development of both active and passive immunotherapies. Based in Gothenburg, Alzinova AB operates in the biotechnology and medical research sector, where it contributes to the broader effort to create disease-modifying therapies for neurodegenerative disorders.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 24M
▼ -27.8% YoY
Op. Margin
–
ROIC
-16.35%
▼ -2.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 44M
▼ -6.8% YoY
Op. Cash Flow (TTM)
-kr 24M
▲ +35.7% YoY
Net Debt
kr 481K
Cash & Equiv.
kr 319K
Continue Research
Peers
Biotechnology · Pick stocks to compare with ALZ.XSTO
Alzinova AB (ALZ.XSTO) in three numbers
Questions about Alzinova AB
Is Alzinova AB a high-quality business?
Alzinova AB scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at 441.9%. The Quality tab shows every check against its target.
Does Alzinova AB (ALZ.XSTO) pay a dividend?
No. Alzinova AB (ALZ.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ALZ.XSTO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.